TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Zhaoke Ophthalmology Ltd. ( (HK:6622) ) is now available.
Zhaoke Ophthalmology Limited has announced that the National Medical Products Administration of China has accepted its Biologics License Application for TAB014, a treatment for wet age-related macular degeneration (wAMD). This marks the first bevacizumab-based antibody filing for wAMD in China, following successful Phase III clinical trials. The company has secured full control over the development and commercialization of TAB014 in China, Hong Kong, and Macau, through an agreement with TOT BIOPHARM Co., Ltd. The acceptance of this application positions Zhaoke Ophthalmology as a significant player in the rapidly growing wAMD market, which is expected to expand significantly by 2030.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company focused on the ophthalmology industry, primarily developing treatments for eye-related conditions. One of its core products is TAB014, a recombinant humanized anti-VEGF monoclonal antibody for wet age-related macular degeneration (wAMD). The company is involved in clinical research and aims to provide cost-effective therapies for vision loss and blindness, particularly in the Chinese market.
Average Trading Volume: 2,840,948
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.72B
For a thorough assessment of 6622 stock, go to TipRanks’ Stock Analysis page.